{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:05:23Z","timestamp":1767704723126,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":857,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To evaluate the safety of double\u2010dose transdermal scopolamine patch therapy.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Randomized, crossover, double\u2010blind study.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Motion sickness clinic in Haifa, Israel.<\/jats:p><jats:p><jats:bold>Participants.<\/jats:bold> Twenty male sailors aged 18\u201321 years whose seasickness symptoms improved only slightly or not at all with a single transdermal scopolamine patch.<\/jats:p><jats:p><jats:bold>Intervention.<\/jats:bold> Subjects received either two transdermal scopolamine patches or one scopolamine patch plus a placebo patch for 24 hours (first session). After at least 1 week from the end of the first session, they received the other treatment for 24 hours (second session).<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> Plasma scopolamine concentrations, physiologic (heart rate and blood pressure), visual, and cognitive function parameters, and adverse effects were assessed before the first session (baseline) and after each 24\u2010hour session. Visual function was tested again 24 hours after patch removal. Subjects also completed an adverse\u2010effects questionnaire immediately after and 24 hours after patch removal for both treatment sessions. A significant difference was found in mean plasma scopolamine concentrations between the single\u2010dose and double\u2010dose treatments (81 vs 127 pg\/ml [therapeutic level 100 pg\/ml], p&lt;0.01). No significant differences were found in heart rate, blood pressure, cognitive function, or visual function measurements. Mild blurred vision was the only adverse effect for which there was a significant difference between the single\u2010dose and double\u2010dose treatments; however, this adverse effect was judged to be not clinically significant.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Double\u2010dose transdermal scopolamine may improve treatment in patients who fail to respond to a single patch by increasing the plasma scopolamine concentration, without aggravating systemic, visual, or cognitive adverse effects. Thus we recommend that a double dose can be administered safely to these patients.<\/jats:p>","DOI":"10.1592\/phco.29.9.1082","type":"journal-article","created":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T10:31:15Z","timestamp":1250850675000},"page":"1082-1088","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of Double\u2010Dose Transdermal Scopolamine"],"prefix":"10.1002","volume":"29","author":[{"given":"Ronen","family":"Bar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amnon","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dror","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"volume-title":"Motion sickness","year":"1975","author":"Reason JT","key":"e_1_2_1_2_2"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-303040-5.50011-8"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645060-00001"},{"issue":"3","key":"e_1_2_1_5_2","first-page":"CD002851","article-title":"Scopolamine (hyoscine) for preventing and treating motion sickness","author":"Spinks A","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198529030-00001"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.57"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016488509182265"},{"key":"e_1_2_1_9_2","first-page":"766","article-title":"Scopolamine patch to prevent seasickness: clinical response vs plasma concentration in sailors","volume":"76","author":"Gil A","year":"2005","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_10_2","first-page":"60","article-title":"Efficacy of transdermal scopolamine against seasickness: a 3\u2010day study at sea","volume":"58","author":"Attias J","year":"1987","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_11_2","first-page":"258","article-title":"Transdermal delivery of scopolamine for prevention of motion\u2010induced nausea in rough seas","volume":"2","author":"Price N","year":"1979","journal-title":"Clin Ther"},{"key":"e_1_2_1_12_2","first-page":"1051","article-title":"Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo: a comparative study at sea","volume":"55","author":"Noy S","year":"1984","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_13_2","first-page":"467","article-title":"Rate of absorption of scopolamine after application of Scopoderm\u2010TTS [abstract]","volume":"66","author":"Doweck I","year":"1995","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-3565(24)29671-3","article-title":"Scopolamine bioavailability in combined oral and transdermal delivery","volume":"296","author":"Nachum Z","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_15_2","first-page":"117","article-title":"Transdermally administered scopolamine for prevention of motion sickness in a vertical oscillator [abstract]","volume":"21","author":"Shaw JE","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760413"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(83)80048-X"},{"issue":"5","key":"e_1_2_1_18_2","first-page":"81","article-title":"Pharmacokinetics of free and glucuronidated scopolamine following transdermal delivery of scopolamine in children [abstract]","volume":"59","author":"Ensing K","year":"1986","journal-title":"Acta Pharmacol Toxicol Copenh"},{"key":"e_1_2_1_19_2","first-page":"1096","article-title":"Prevention of experimental motion sickness by scopolamine absorbed through the skin","volume":"47","author":"Graybiel A","year":"1976","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_20_2","first-page":"770","article-title":"Antimotion\u2010sickness efficacy of scopolamine 12 and 72 hours after transdermal administration","volume":"53","author":"Graybiel A","year":"1982","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6296.875"},{"key":"e_1_2_1_22_2","first-page":"186","volume-title":"Drug absorption","author":"Shaw JE","year":"1981"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600730432"},{"key":"e_1_2_1_24_2","first-page":"325","article-title":"Use of percutaneous absorption for systemic administration of drugs","volume":"215","author":"Shaw JE","year":"1975","journal-title":"Pharm J"},{"key":"e_1_2_1_25_2","first-page":"240","article-title":"The effect of transdermal therapeutic system\u2010scopolamine in controlling acute vertigo [abstract]","volume":"87","author":"Fee WE","year":"1979","journal-title":"Otolaryngol Head Neck Surg"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470030208"},{"key":"e_1_2_1_27_2","first-page":"1","article-title":"Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning","volume":"60","author":"Parrott AC","year":"1989","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_28_2","first-page":"236","article-title":"Transdermal scopolamine: human performance and side effects","volume":"57","author":"Gordon C","year":"1986","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_29_2","first-page":"209","article-title":"Comparison of performance under the influence of three antimotion sickness drugs [abstract]","volume":"69","author":"Gonen A","year":"1998","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(91)90031-X"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.9.1082","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.9.1082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:55:38Z","timestamp":1761040538000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.9.1082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1592\/phco.29.9.1082"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.9.1082","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}